Drug Trial Radar · NCT05822544
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
564
Planned (sponsor's estimate)
Start
Apr 22, 2023
Primary completion
Sep 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- OrsoBio, IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects. The phase 1b portion of the study is designed to assess the safety, tolerability, and PK of TLC-6740 in subjects with obesity, with or without type 2 diabetes mellitus.
Conditions
- Healthy Subjects
- Obesity
- Type 2 Diabetes
Interventions
TLC-6740 Oral SolutionDrug
Oral solution of TLC-6740
Placebo Oral SolutionOther
Placebo-to-match oral solution TLC-6740
TLC-6740 TabletDrug
Tablet formulation of TLC-6740
Drug Metabolizing EnzymeDrug
Oral dose of omeprazole, voriconazole, itraconazole, or rifampicin
TirzepatideDrug
Subcutaneous injection of tirzepatide
Placebo TabletOther
Placebo-to-match tablet formulation of TLC-6740
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of TLC-6740 treatment-emergent adverse eventsTime frame: Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study
- PK of TLC-6740 AUCTime frame: Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study
- PK of TLC-6740 CmaxTime frame: Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study
- PK of TLC-6740 tmaxTime frame: Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study
- PK of TLC-6740 t1/2Time frame: Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study
- PK of TLC-6740 CL/FTime frame: Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 168 (Parts F, G) of the study
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
OrsoBio Auckland Research Site 1
Auckland, New Zealand
OrsoBio Auckland Research Site 2
Auckland, New Zealand
OrsoBio Auckland Research Site 3
Auckland, New Zealand
OrsoBio Research Site
Christchurch, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.